NYSE:QGEN - Qiagen Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $34.60 +0.09 (+0.26 %) (As of 11/16/2018 04:00 PM ET)Previous Close$34.60Today's Range$34.15 - $34.7652-Week Range$30.64 - $39.45Volume451,354 shsAverage Volume1.00 million shsMarket Capitalization$7.96 billionP/E Ratio27.24Dividend YieldN/ABeta1.02 ProfileDiscussionAnalyst RatingsChartEarningsHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands. Receive QGEN News and Ratings via Email Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:QGEN Previous Symbol CUSIPN/A Webwww.qiagen.com Phone31-77-355-6600 Debt Debt-to-Equity Ratio0.42 Current Ratio1.37 Quick Ratio1.25 Price-To-Earnings Trailing P/E Ratio27.24 Forward P/E Ratio26.02 P/E Growth2.17 Sales & Book Value Annual Sales$1.42 billion Price / Sales5.57 Cash Flow$2.3331 per share Price / Cash14.83 Book Value$11.07 per share Price / Book3.13 Profitability EPS (Most Recent Fiscal Year)$1.27 Net Income$40.39 million Net Margins6.00% Return on Equity12.52% Return on Assets6.14% Miscellaneous Employees4,688 Outstanding Shares228,230,000Market Cap$7.96 billion OptionableOptionable Qiagen (NYSE:QGEN) Frequently Asked Questions What is Qiagen's stock symbol? Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN." How were Qiagen's earnings last quarter? Qiagen NV (NYSE:QGEN) announced its earnings results on Monday, October, 29th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.33 by $0.02. The firm earned $377.91 million during the quarter, compared to analysts' expectations of $382.16 million. Qiagen had a return on equity of 12.52% and a net margin of 6.00%. View Qiagen's Earnings History. What price target have analysts set for QGEN? 10 Wall Street analysts have issued 12-month price objectives for Qiagen's shares. Their forecasts range from $38.00 to $44.00. On average, they anticipate Qiagen's stock price to reach $41.00 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Qiagen. What is the consensus analysts' recommendation for Qiagen? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last year. There are currently 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Qiagen. Has Qiagen been receiving favorable news coverage? News headlines about QGEN stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Qiagen earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Qiagen's key competitors? Some companies that are related to Qiagen include NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Seattle Genetics (SGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP). Who are Qiagen's key executives? Qiagen's management team includes the folowing people: Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 52)Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 49)Mr. John Gilardi, VP of Corp. Communications & Investor RelationsMr. Jean-Pascal Viola, Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VPDr. Annette Koch, Sr. VP & Chief HR Officer How do I buy shares of Qiagen? Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Qiagen's stock price today? One share of QGEN stock can currently be purchased for approximately $34.60. How big of a company is Qiagen? Qiagen has a market capitalization of $7.96 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $1.27 on an earnings per share basis. Qiagen employs 4,688 workers across the globe. What is Qiagen's official website? The official website for Qiagen is http://www.qiagen.com. How can I contact Qiagen? Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected] MarketBeat Community Rating for Qiagen (NYSE QGEN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 87 (Vote Outperform)Underperform Votes: 100 (Vote Underperform)Total Votes: 187MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/17/2018 by MarketBeat.com StaffFeatured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?